EUVIMEDEUVIMED entdecken
Crossref

Belumosudil in patients with bronchiolitis obliterans syndrome phenotype of chronic lung allograft dysfunction: An exploratory single-center real-world retrospective study

Xiaohua Wang, Lulin Wang, Jia Liu, Peihang Xu, Qiaoyan Lian, Xin Xu, Jianxing He, Chunrong Ju

Transplant Immunology · 2026

DOI: 10.1016/j.trim.2026.102450 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2026. Verfasst von Xiaohua Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Organ Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Lung Transplantation, Bronchiolitis Obliterans Syndrome, Graft Rejection, Bronchiolitis Obliterans. Die Arbeit nennt 16 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wu Jieping Medical Foundation, State Key Laboratory of Respiratory Disease.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic lung allograft dysfunction (CLAD) is a major cause of post-lung transplant mortality, with limited medical treatment options. This exploratory single-center real-world retrospective study aimed to evaluate the clinical outcomes and safety of belumosudil in lung transplant recipients with the bronchiolitis obliterans syndrome (BOS) phenotype of CLAD. METHODS: An exploratory single-center real-world retrospective study was conducted of lung transplant recipients with CLAD-BOS who received belumosudil for at least 3 months between September 2024 and November 2025. Primary endpoint was treatment response to belumosudil as classified based on changes in forced expiratory volume in 1 s (FEV1). RESULTS: A total of 17 CLAD-BOS patients were included (9 CLAD stage 1-2 patients and 8 CLAD stage 3-4 patients). Treatment response to belumosudil was assessed at 3, 6, and 12 months after initiating belumosudil. At 3 months, 17.6% of patients achieved a response, 64.7% remained stable, and 17.6% were non-responders. At 6 and 12 months, most patients showed stabilization or improvement in FEV1 (6 months: 68.8%, 11/16; 12 months: 70%, 7/10), while a minority exhibited a continued decline. All CLAD stage 1-2 patients achieved response or stabilization at 3 months, while no responses were observed in CLAD stage 3-4 patients. This stage-dependent pattern persisted at 6 and 12 months. Mixed-model analyses confirmed more favorable changes in FEV1 and forced vital capacity (FVC) in early-stage patients. No significant adverse events were observed. CONCLUSIONS: This exploratory single-center real-world study provides preliminary hypothesis-generating evidence that belumosudil may be associated with stabilization of pulmonary function in lung transplant recipients with CLAD-BOS, particularly when initiated during earlier disease stages. These findings require confirmation in larger prospective controlled studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationBronchiolitis Obliterans SyndromeGraft RejectionBronchiolitis ObliteransHumansFemaleRetrospective StudiesMaleMiddle AgedAdultTreatment OutcomeChronic DiseasePhenotypeForced Expiratory VolumeAllograftsAcetamides

Stichwörter der Autor:innen

BelumosudilBronchiolitis obliterans syndromeChronic lung allograft dysfunctionLung transplantationPulmonary function

Substanzen

belumosudilAcetamides

Autor:innen und Institutionen

  • Department of Organ Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China.
  • Department of Respiratory Medicine, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Department of Organ Transplantation, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China. Electronic address: juchunrong@gzhmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Wu Jieping Medical Foundation
  • State Key Laboratory of Respiratory Disease
  • Guangzhou Medical University

Zitieren

APA

Wang, X., Wang, L., Liu, J., Xu, P., Lian, Q., Xu, X., He, J., & Ju, C. (2026). Belumosudil in patients with bronchiolitis obliterans syndrome phenotype of chronic lung allograft dysfunction: An exploratory single-center real-world retrospective study. Transplant Immunology. https://doi.org/10.1016/j.trim.2026.102450

Vancouver

Wang X, Wang L, Liu J, Xu P, Lian Q, Xu X, et al. Belumosudil in patients with bronchiolitis obliterans syndrome phenotype of chronic lung allograft dysfunction: An exploratory single-center real-world retrospective study. Transplant Immunology. 2026. doi:10.1016/j.trim.2026.102450

BibTeX
@article{Wang2026,
  author = {Wang, Xiaohua and Wang, Lulin and Liu, Jia and Xu, Peihang and Lian, Qiaoyan and Xu, Xin and He, Jianxing and Ju, Chunrong},
  title = {Belumosudil in patients with bronchiolitis obliterans syndrome phenotype of chronic lung allograft dysfunction: An exploratory single-center real-world retrospective study},
  journal = {Transplant Immunology},
  year = {2026},
  doi = {10.1016/j.trim.2026.102450}
}
Kostenlos starten →